ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 149

Deep Immune-Profiling of CD4+ T Cells in Behçet’s Disease

Johannes Nowatzky1, Arshed Al-Obeidi2, Yuhe Xia2 and Olivier Manches3, 1Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 2NYU School of Medicine, New York, NY, 3INSERM, Grenoble, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, T cells and T-Regulatory Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Functionality and immune-phenotypes of the human CD4+ T-cell compartment in Behçet’s disease (BD) are under-investigated, but several lines of evidence point to its relevance in the pathogenesis and progression of the disease. We aimed to apply an unbiased single cell approach to dissect the immune-phenotype of CD4+ T cells in prototypical BD in order to identify cell populations of potential pathobiological relevance.

Methods: We determined single cell expression levels of CD3, CD4, CD8, CD127, CD25, CD45RA, CCR7, FoxP3, HELIOS, Ki76, HLA-DR, CD38, CD39 in PBMC by flow cytometry and computed the representation of all possible cell populations within CD4+ starting populations in PBMC from healthy (HD, n=25), BD (n=13), and diseased subjects with non-BD auto-immune uveitis (n=11, VKH, Sarcoidosis, and HLA-B27 associated uveitis). BD subjects met ISG criteria and were Arab or Chinese. 62% had pan-uveitis, 23% major vascular disease, and 7% parenchymal CNS disease. 46% were HLA-B51 carriers.

Results: Computation of all populations defined by 8 markers (CD127, CD25, CD45RA, CCR7, FoxP3, HELIOS, Ki67, HLA-DR) within the CD4+ T cell compartment yielded a total of 6,560 cell populations per subject out of which 45 reached significance (p<=0.000001) differentiating 3 groups (BD, non-BD uveitis, and HD). All of these populations comprised sub-types of the human regulatory T (Treg) cell compartment with strong predominance of non-proliferating, non-activated, FoxP3+Helios+ Treg carrying central-memory phenotypes (CD45RA–, CCR7+). 2-group testing of BD vs non-BD revealed 43 distinct cell populations at a significance level of p <=0.002 representing CD25+ non-Treg; comparison of BD vs HD uncovered 58 populations at significance level of p <=0.0001 representing FoxP3+Helios+ subpopulations, and non-BD vs HD identified 61 populations at p<=0.001, comprising CD25+CD127+/- FoxP3+/-, but consistently HELIOS–, presumably non-Treg populations. A separate analysis using 6 marker combinations (CD38, CD39, CD226, TIGIT, CD45RA, CCR7) within the CD3+CD4+CD8–CD127–CD25+compartment which contains most human Treg, showed 48 populations (p <=0.0001) in 3-way comparison (BD, non-BD uveitis, and HD) pointing to high significance of TIGIT and CD226, and 18 populations with differential expression of CD39+ between BD and non-BD diseases subjects. TIGIT and CD226 co-expressing Treg (CD127–CD25+) subpopulations also reached significance (p<=0.02) in a longitudinal analysis of 7 BD subjects in active vs inactive disease states, as did 56 out of 6,560 populations within total CD4+CD3+ cells, mostly representing non-Treg cells in active disease.

Conclusion: Differential expression of CD4+ Treg and non-Treg cells shapes the immune-phenotype of BD vs HD and non-BD autoimmune diseases that have phenotypic overlap with BD (uveitis). Populations within the HELIOS+FOXP3+compartment of non-activated, non-proliferating Treg had the highest significance when differentiating BD from HD, suggesting relevance of a true Treg phenotype. Non-Treg CD25+ cell populations seem more indicative of BD vs non-BD uveitic disease as well as of clinically active BD while populations with high CD39 expression may indicate non-BD states.


Disclosure: J. Nowatzky, None; A. Al-Obeidi, None; Y. Xia, None; O. Manches, None.

To cite this abstract in AMA style:

Nowatzky J, Al-Obeidi A, Xia Y, Manches O. Deep Immune-Profiling of CD4+ T Cells in Behçet’s Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/deep-immune-profiling-of-cd4-t-cells-in-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deep-immune-profiling-of-cd4-t-cells-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology